Ronda Dean, Afaxys’ president and CEO, is also the founder of the company. As a senior executive with more than 25 years of accomplishments in the healthcare and pharmaceutical industries, including leadership of both for-profit and non-profit organizations – from start-ups to Fortune 100s – Ms. Dean offers a breadth of experience across various facets of the healthcare industry.
As president and CEO of Afaxys, Ms. Dean has led start-up operations and the successful execution of a $12 million capitalization strategy. Prior to her work at Afaxys, Ms. Dean spent 16 years with Parke-Davis Pharmaceuticals, a division of Warner Lambert, where she progressed quickly into executive management. Prior to the company’s merger with Pfizer, she served as vice president and general manager of women’s healthcare, leading a 300-person business unit through a period of accelerated growth. This expansion firmly established Parke-Davis as a leader in the women’s healthcare space, building it from a small, one-category business to a multi-category, key revenue and profit generator. During this time, Ms. Dean served on the company’s management team providing strategic and operational guidance to the U.S. pharmaceutical business. Ms. Dean’s career began at Riverside Methodist Hospital. Over the years, she has sat on numerous boards, including Johns Hopkins Medical Institutions, the Storm Eye Institute at Medical University of South Carolina, Wings for Kids and serves on the Finance Committee of the Coastal Community Foundation.
Ms. Dean holds an M.B.A. from the Fuqua School of Business at Duke University and a B.S. in Allied Health Sciences from The Ohio State University.